<?xml version='1.0' encoding='utf-8'?>
<document id="11465417"><sentence text="Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions."><entity charOffset="37-48" id="DDI-PubMed.11465417.s1.e0" text="simvastatin" /><entity charOffset="52-64" id="DDI-PubMed.11465417.s1.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.11465417.s1.e0" e2="DDI-PubMed.11465417.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11465417.s1.e0" e2="DDI-PubMed.11465417.s1.e1" /></sentence><sentence text="To evaluate an interaction between simvastatin and itraconazole in in vitro studies and to attempt a quantitative prediction of in vivo interaction in humans"><entity charOffset="35-46" id="DDI-PubMed.11465417.s2.e0" text="simvastatin" /><entity charOffset="51-63" id="DDI-PubMed.11465417.s2.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.11465417.s2.e0" e2="DDI-PubMed.11465417.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11465417.s2.e0" e2="DDI-PubMed.11465417.s2.e1" /></sentence><sentence text="" /><sentence text="The inhibitory effect of itraconazole on simvastatin metabolism was evaluated using human liver microsomes and the Ki values were calculated for the unbound drug in the reaction mixture"><entity charOffset="25-37" id="DDI-PubMed.11465417.s4.e0" text="itraconazole" /><entity charOffset="41-52" id="DDI-PubMed.11465417.s4.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11465417.s4.e0" e2="DDI-PubMed.11465417.s4.e0" /><pair ddi="false" e1="DDI-PubMed.11465417.s4.e0" e2="DDI-PubMed.11465417.s4.e1" /></sentence><sentence text=" A physiologically-based pharmacokinetic model was used to predict the maximum in vivo drug-drug interaction" /><sentence text="" /><sentence text="Itraconazole competitively inhibited the metabolism of simvastatin to M-1 and M-2 with Ki values in the nM range"><entity charOffset="0-12" id="DDI-PubMed.11465417.s7.e0" text="Itraconazole" /><entity charOffset="55-66" id="DDI-PubMed.11465417.s7.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11465417.s7.e0" e2="DDI-PubMed.11465417.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11465417.s7.e0" e2="DDI-PubMed.11465417.s7.e1" /></sentence><sentence text=" The area under the curve (AUC) of simvastatin after concomitant dosing with itraconazole was predicted to increase ca"><entity charOffset="35-46" id="DDI-PubMed.11465417.s8.e0" text="simvastatin" /><entity charOffset="77-89" id="DDI-PubMed.11465417.s8.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.11465417.s8.e0" e2="DDI-PubMed.11465417.s8.e0" /><pair ddi="false" e1="DDI-PubMed.11465417.s8.e0" e2="DDI-PubMed.11465417.s8.e1" /></sentence><sentence text=" 84-101-fold compared with that without administration of itraconazole"><entity charOffset="58-70" id="DDI-PubMed.11465417.s9.e0" text="itraconazole" /></sentence><sentence text=" Taking into consideration the fact that this method predicts the maximum interaction, this agrees well with the clinical observation of a 19-fold increase" /><sentence text=" A similar prediction, based on the Ki value without taking into account the drug adsorption to microsomes, led to an underevaluation of the interaction" /><sentence text="" /><sentence text="It was demonstrated that the competitive inhibition of CYP3A4-mediated simvastatin metabolism by itraconazole is the main cause of the drug interaction and that a Ki value corrected for drug adsorption to microsomes is the key factor in quantitatively predicting the maximum in vivo drug interactions"><entity charOffset="71-82" id="DDI-PubMed.11465417.s13.e0" text="simvastatin" /><entity charOffset="97-109" id="DDI-PubMed.11465417.s13.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.11465417.s13.e0" e2="DDI-PubMed.11465417.s13.e0" /><pair ddi="false" e1="DDI-PubMed.11465417.s13.e0" e2="DDI-PubMed.11465417.s13.e1" /></sentence><sentence text="" /></document>